Arthi Thirumalai is an Endocrinology/Metabolic physician affiliated with University of Washington. OpenAlex indexes 54 publications with 636 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1959 NE Pacific St Box 356426
Univ Of Washington, Division Of Endocrinology
Seattle, WA 981956426
Telephone
206-543-3470Registry record last updated 16 Jul 2013.
Clinical trials
- Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
Sponsor: University of Washington
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20253 payments
- Abbott LaboratoriesProgram year20241 payment
- Novo Nordisk IncProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
65.7%GLP-1 receptor agonist21.1%Mounjaro45%Ozempic43%Trulicity12%Part D<11 patientsInsulin Analog20.9%Lantus Solostar41%Humalog Kwikpen U-10021%Novolog Flexpen15%Basaglar Kwikpen U-10013%Insulin Lispro Kwikpen U-10010%Part D<11 patients+ 3 more classes in this area
Cardiovascular
23%Statin9.4%Rosuvastatin Calcium84%Atorvastatin Calcium16%Part D<11 patientsPCSK9 Inhibitor7.9%Repatha Sureclick100%Part D≥13 patients+ 1 more class in this area
Hormonal (systemic)
8.3%l-Thyroxine6.5%Levothyroxine Sodium100%Part D≥18 patientsVasopressin Analog1.7%Desmopressin Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Waist Circumference as a Predictor of Hepatic Steatosis and Fibrosis in the NHANES 2017–2018 Cohort
Metabolic Syndrome and Related Disorders
2026 - Su2085 ARE PRIMARY CARE PHYSICIANS COMFORTABLE WITH DIAGNOSIS AND MANAGEMENT OF MASLD?
Gastrointestinal Endoscopy
2026 - Su2111 ADDRESSING UNDERDIAGNOSE OF MASLD IN PRIMARY CARE: A QUALITY IMPROVEMENT AND EDUCATIONAL INTERVENTION
Gastrointestinal Endoscopy
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Neal Futran, MD, DMD
University of Washington
Elizabeth Swisher
University of Washington
David Tirschwell
University of Washington
Elaine Peskind, MD
University of Washington
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”